Kornimate/medical-research-clean huggingface dataset:
comparison between the role of transabdominal ultrasound versus transvaginal ultrasound in evaluation of placental invasion in cases of placenta previa anterior wall with previous uterine scar

Conditions: Placenta Accreta

Summary: objective: to compare between the role of transabdominal ultrasound versus transvaginal ultrasound in evaluation of placental invasion in cases of placenta previa anterior wall with previous uterine scar applying the unified ultrasonographic descriptors suggested by the european working group on abnormally invasive placenta "ew-aip' also to evaluate the sensitivity and specificity of each criterion by comparing them with the final outcome of pregnancy fifty pregnant women with persistent placenta previa (after 28 weeks' gestation) were prospectively enrolled into this study. both transabdominal and transvaginal ultrasound were performed by two different operators who were blinded to the results of each other. the placenta was studied as regarding the exact loacalization and the unified descriptors were applied and evaluated by tas and tvs. the ultrasound findings were analyzed with reference to the final diagnosis made during cesarean delivery and histopathological examination

definitive diagnosis of abnormally invasive placenta was made at delivery when the myometrium was seen to be invaded by the placenta, and the pathological examination of the removed uterus showed the villi attached to the myometrium without intervening decidua (accreta), invading into the myometrium (increta) or reaching the serosa (percreta). -complete imaging using all diagnostic techniques (gray-scale, color doppler) by both transabdominal and transvaginal by two expert operators, then an offline analysis of the acquired images \& volumes was done ultrasound examination was performed using a 2d ultrasound system equipped with a 4-8-mhz trans-abdominal transducer and a 12 mhz transvaginal transducer the transvaginal ultrasound was performed by a highly experienced operator whereas the transabdominal ultrasound was performed by a less experienced one and both were blinded from the results of each other placenta was examined while the bladder was partially full about 300 ml for adequate visualization and precise localization the examined placenta is considered to be suspicious of abnormal invasion in case of having one or more of the unified descriptors described by the european working group on abnormally invasive placenta "ew-aip":

Eligibility criteria:
inclusion criteria: * pregnant women in the reproductive age group (18 - 45) diagnosed persistent placenta previa anterior wall after 28 weeks of gestation , with history of previous caesarian section and/or any other type of uterine surgeries exclusion criteria: * placenta previa posterior wall * unscarred uterus
safety & efficacy of tc-5619 in adults with inattentive-predominant attention deficit/hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: study is to assess if tc-5619 improves symptoms for adults diagnosed with the inattentive-predominant subtype of adhd over a 4-week treatment period.

a 3-arm, double-blind, randomized, placebo-controlled, multicenter, fixed dose study to assess efficacy and safety of tc-5619 in adults with inattentive-predominant attention deficit/hyperactivity disorder (adhd) utilizing the connor's adult adhd rating scale-investigator completed version (caars-inv) inattentive subscale scores through 4 weeks of treatment.

Eligibility criteria:
inclusion criteria: 1. diagnosis of inattentive predominant adhd per dsm-iv tr) criteria at screening 2. score ≥ 2 on at least 6 of 9 items in the inattentive subscale of the caars-inv at baseline (day 1) 3. score of \< 2 on at least 4 of 9 items in the hyperactive/impulsivity subscale of the caars-inv at baseline (day 1) 4. score ≥ 4 (at least moderate) on the cgi-s 5. tobacco non-users as indicated by lack of tobacco use within the last 6 months prior to screening, and by negative urinary cotinine level of \< 50 ng/ml after quantification exclusion criteria: 1. current dsm-iv axis i psychiatric disorder other than adhd; 2. use of tobacco cessation agents within 4 weeks prior to screening 3. known or suspected drug abuse within the last 6 months prior to screening 4. urine drug screen positive for illegal or non-prescribed drugs at screening 5. patients at imminent risk of suicide or of danger to themselves or others as judged by the investigator 6. use of drugs affecting cognitive function within 4 weeks prior to day 1. this includes use of any concomitant medications for treatment of adhd. 7. history of significant other major or unstable neurological, metabolic, hepatic, renal, hematological, pulmonary, cardiovascular (cv), gastrointestinal (gi), or urological disorder; or diagnosis of major depressive disorder 8. myocardial infarction within past year 9. seizure disorder within past year 10. type 1 diabetes mellitus (dm); type 2 dm that requires medication (diet-controlled allowed) 11. hba1c \> 7.4 at screening 12. bmi \ 35; male weight \< 100 lbs; female weight \< 80 lbs. 13. current tuberculosis (tb) or known systemic infection \[hepatitis b virus (hbv), hepatitis c virus (hcv), human immunodeficiency virus (hiv)\] 14. women of child-bearing potential and male participants unwilling or unable to use accepted methods of birth control 15. participation in another central nervous system (cns)-related clinical trial in the last 3 months and any other clinical trial in last 30 days prior to screening, or participation in a previous tc-5619 clinical trial

Keywords: adhd
micro-rna profile in patients with different stages of atherosclerosis according to cta

Conditions: Ischemic Heart Disease; Atherosclerosis

Summary: the main purpose of this single-center study is to determine the spectrum and levels of cardiospecific circulating micrornas in patients with different stages of atherosclerosis according to 640-slice multispiral computed tomography (msct).

the study will be conducted in two phases. phase one. after signing the informed consent, patients with coronary heart disease, angina pectoris ii-iv functional class, who underwent msct angiography of the coronary arteries for medical reasons, regulated in the relevant esc and the russian society of cardiology guidelines, will be included in the study. according to the results of msct, the participants will be divided into 4 groups: those with atherosclerotic plaques with signs of instability; those with stable atherosclerotic plaques without marked calcification; those with calcined atherosclerotic plaques; those with no signs of atherosclerosis of the coronary arteries. plasma samples will be analyzed by microarray, using a cardiospecific set. phase two. validation of the results obtained after the first phase will be performed on a larger sample of patients. patients after signing an informed consent will also undergo msct angiography of coronary arteries and according to its results will be devided in 4 groups. to assess the level of microrna expression in the blood of patients, real-time reverse transcription-polymerase chain reaction (rt-pcr) will be used. the expected result of the study. for the first time ever, there will be determined the profile of circulating regulatory rna in patients who underwent msct angiography of coronary arteries. features of expression of circulating micrornas will be compared with different severity degrees of the atherosclerotic process based on msct criteria. the results will be compared with each other (including the "control" group), which will allow to identify common patterns and specific differences.

Eligibility criteria:
inclusion criteria: * written informed consent of the patient to participate in the study; * age 18-80; * the presence of medical indications for msct angiography of coronary arteries in connection with suspected coronary heart disease. exclusion criteria: * age less than 18 or more than 80; * pregnancy, breast-feeding; * patients who have not undergone (and do not plan) msct coronary angiography; * any surgical intervention on the heart in history; * severe heart failure (iii-iv nyha classes); * history of myocardial infarction; * the body mass index of 35 or more; * more than twice the alt and/or ast level; * the presence of severe somatic pathology (except coronary atherosclerosis); * patient's refusal to participate in the study;

Keywords: ischemic heart disease atherosclerosis micro-rna multislice spiral computed tomography coronary angiography
stereotactic body radiation therapy (sbrt) in the treatment of liver tumors

Conditions: Liver Tumors

Summary: patients with primary hepato-biliary malignancies or liver metastases from gastrointestinal cancer suffer substantial morbidity and mortality from their hepatic disease. curative resection is feasible only for selected subgroups of patients. the majority of patients have unresectable and incurable disease. aggressive arterial and systemic chemotherapy have been used in recent years with improved response and survival. however, a significant number of patients, at least one-third of patients with liver metastases from colorectal cancer and two-third or higher of unresectable hepatobiliary cancer, continue to die of liver failure from progressive disease in the liver. percutaneous ethanol injections, chemoembolization, cryotherapy and thermal ablation using radiofrequency have been used to treat selected patients with smaller tumors (3-4 cm) in areas away from major blood vessels and the biliary tract. however, most unresectable liver cancers did not fit the criteria for these treatments. therefore, other regional therapeutic option like external radiation therapy may be considered for local control in the liver or symptom palliation


Eligibility criteria:
inclusion criteria: * histologically conformation of liver malignancy * solitary or multiple liver tumors amenable to sbrt * no jaundice or liver dysfunction * for metastases, the primary tumor site has been adequately treated. * for primary hepatoma, no extra-hepatic disease * karnofsky \> 70 exclusion criteria: * no extra-hepatic disease * liver failure or inadequate liver function * ascites * previous radiation therapy to the liver * lesions invading major blood vessels in the porta region * contraindication to receive radiation therapy in the liver

Keywords: liver malignancy stereotactic body radiation therapy efficacy of sbrt in liver tumors hepatic toxicity with sbrt
radicle recharge: a study of health and wellness products on energy levels and other health outcomes

Conditions: Energy; Fatigue

Summary: a randomized, double blind, placebo-controlled trial assessing the immediate impact of non-caffeinated supplements on energy levels and associated health outcomes

this is a randomized, double blind. placebo-controlled study conducted with adult participants (study volunteers, citizen scientists), at least 21 years of age at the time of consent and attending the supply side west meeting (ssw) this year. eligible participants will (1) endorse a desire for more energy and (2) express acceptance in taking a product and not knowing its formulation until the end of the study. participants that report a known contraindication or with well-established, significant safety concerns due to illness and/or medication(s) will be excluded. participants that report a known allergy to any possible ingredient they may be exposed to in one of the study arms will be excluded. participants will take their assigned study product at a radicle booth, after enrolling. participant reported outcomes (pros) are collected electronically from eligible participants at baseline (before study product consumption, and for a period of 5 hours after consuming their study product.

Eligibility criteria:
inclusion criteria: * adults at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, sexes, and gender identities * attending the supply side west meeting in person * able to read and understand english * endorses more energy as a primary desire * expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study exclusion criteria: * reports being pregnant, trying to become pregnant, or breastfeeding * reports current enrollment in another clinical trial * reports a cardiac disease that presents an absolute contraindication and/or a significant safety concern with any of the study product ingredients. * reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study products ingredients: anticoagulants, chemotherapy, immunotherapy, medications that warn against grapefruit consumption, oral diabetic medications, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection * reports an allergy to any of the study products ingredients
evaluation of sodb® in metabolic adaptations in overweight women

Conditions: Overweight

Summary: the objective of this study is to evaluate the influence of a 3 months sodb® supplementation in adipose tissue modulations of overweight women, in comparison to a placebo.

beneficial experimental results have already been obtained with sodb®. that is why, the investigators expect several effects of sodb® here. indeed, this clinical study could show that sodb® is able to induce endogenous antioxidant defence, and then reduce oxidative stress generally observed in overweight adipose tissue. moreover, this study could evaluate the impact of a decrease in oxidative stress on the others overweight-induced disorders, such as insulin resistance, inflammation, fibrosis, lipolyse alterations.

Eligibility criteria:
inclusion criteria: * overweight women (imc 25-30 kg/m2) * stable weight (variation \<5% over the last 3 months) * age between 25 and 50 years old * cellulite grade ≥ 2 * women with genital activity * regular menstrual cycles (28 ± 2 days over the last 3 months) * women with efficient contraception (oral, intra-uterine, ligature trunks or other surgery) - same contraception over the last 3 months * women having given her free, informed and express consent. * affiliated with a social security insurance or beneficiary of such an insurance system. * glycemia \< 1,26g/l * arterial blood pression \< 140/90 mm hg or stable for at least 2 months * ldl cholesterol \<1,90g/l * triglycerides \<2,50g/l exclusion criteria: * untreated dyslipidemia * unstable hypertension * type 1 or 2 diabetes * any history of bariatric surgery * any history of unstable thyroidian diseases * any troubles of hemostasis * any allergy to utilized antiseptic, xylocaine, or to one of the compounds of the experimental or placebo product * excessive coffee consumption (\> 6 cups/day) * consumption of drinks containing xanthic bases (\> 0.5 l/day) * consumption of drinks containing grapefruit juice (\> 0.5 l/day) * consumption of drinks containing plants (\> 2 l/day) * medication with draining, lipolytic, anorexigenic activity * current or recent (in the previous month) antioxidant supplementation (vitamine a, c, e, beta-carotene, lutein, lycopene, selenium) * recent (in the previous year) local anti-cellulite treatment * thigh liposuction in the last 2 years * under current anticoagulant treatment * under current neuroleptic treatment * under current corticotherapy (local or systemic) treatment * under current diuretic treatment * under current antiinflammatory treatment that cannot be interrupted * under current treatment which interferes with autonomous nervous system and lipids metabolism * triglycérides \> 2.50g/l * ldl cholesterol \>1.90 * positive serology for hepatitis b, c and hiv * consumption of more than 66g/day of alcohol * venous fragility not allowing to support catheters during the visits. * adult protected by the law * any subject who participated to a clinical assay within the 3 months.

Keywords: superoxyde dismutase melon concentrate oxydative stress overweight women
clinical outcomes of robotic myomectomy

Conditions: Women With Uterine Myoma

Summary: to identify the predictors of perioperative outcomes in women who receive robotic myomectomy

uterine myoma is the most common gynecological tumor. current surgical management was inclusive of conventional abdominal myomectomy, laparoscopy-assisted myomectomy, robotic-assisted myomectomy. the aim of this study was to identify the predictors of perioperative outcomes in women who receive robotic myomectomy

Eligibility criteria:
inclusion criteria * \>20 years old women * women who received robotic myomectomy
the use of mucograft® to treat gingival recession

Conditions: Gingival Recession

Summary: twenty patients with gingival recession will be enrolled in this trial. gingival recession will be treated in one side by applying mucograft® with coronally advanced flap (caf) while on the opposite side a connective tissue graft (from the palate) will be applied with a caf. patients will be followed for 3 and 6 months by measuring the clinical indexes and statistical analyses will be performed to compare the results and to assess the success of mucograft®.

many surgical techniques have used to treat gingival recession such aas repositioned flaps, autologous soft tissue grafts (connective tissue graft or free gingival grafts) or allografts like acellular dermal which can be used as substitutes for palatal donor tissue. mucograft® (3d collagen matrix) is also an allograft from porcine origin and is designed for soft tissue regeneration and considered the ideal solution to autogenous soft tissue grafts and it provides an ideal matrix for blood vessel and soft tissue ingrowth.

Eligibility criteria:
inclusion criteria: * presence of type i or ii (miller classification) of gingival recession exclusion criteria: * smoking * pregnancy or lactating * presence of any systematic diseases can affect the periodontal surgery. * subjects with significant moderate to severe periodontal disease. * patients under orthodontic treatment * presence of restorative materials (e.g. crown) * effectiveness of frenum * subjects have failed to maintain good plaque control. * subjects having previous surgical treatment for covering the recession in the chosen area.

Keywords: gingival graft free gingival graft coronally advanced flap reduced keratinized gingiva
tablet distraction for pain control during venipuncture

Conditions: Pain Relief

Summary: venipuncture is one of the painful procedures most frequently performed in children. pain and distress management in children, during needle related procedures, is warranted. the base for pain management starts with behavioural and environmental support and distraction. distraction is a cognitive strategy trying to divert the child's attention from a noxious stimulus. active distraction involves the child in a different performance, e.g. playing, during pain procedures. passive distraction redirects the child's attention to visual or auditory stimuli using toys, songs, movies or blowing bubbles. blood-drawing centre is a peculiar setting in which many procedures have to be performed in a limited time. patients usually arrive without a pharmacological premedication and go away immediately after procedure. in this context distraction is an excellent pain relief tool. the aim of the study is to compare the effectiveness of an active distraction (playing a videogame using a computer tablet) with a passive distraction technique in pain relief during venipuncture in a blood-drawing centre.


Eligibility criteria:
inclusion criteria: * age 4 to 13 years * need for venipuncture * informed consent signed by parents or legal guardians exclusion criteria: * children with epilepsy * use of topical, enteral or parenteral analgesics within 8 hours before the procedure * inability to perform venipuncture on hand or arm * children with cognitive impairment or unable to report their pain verbally

Keywords: procedural pain phlebotomy distraction videogame computer tablet child
erythromycin versus azithromycin for preterm prelabor rupture of membranes

Conditions: Premature Rupture of Membrane

Summary: the goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as pprom). current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby are lessened. research shows that antibiotics help the pregnancy last longer, but there have been limited studies about which combination works best. currently, both azithromycin and erythromycin are accepted antibiotic treatments, in addition to ampicillin and amoxicillin. participants diagnosed with pprom will be randomized to receive ampicillin and amoxicillin plus either azithromycin or erythromycin, in addition to the care they would normally receive. studying these two drugs will help decide the best care for future patients with pprom.

preterm pre-labor rupture of membranes (pprom) complicates 3% of pregnancies and accounts for one-fourth to one-third of preterm births. pprom is associated with significant maternal and neonatal morbidities, including chorioamnionitis, endometritis, neonatal sepsis, prematurity-related pathologies. in the absence of labor or indication for immediate delivery, patients who present at less than 34 weeks gestational age are treated with antibiotics to prolong pregnancy until 34 weeks when the risks of prematurity are decreased. based on randomized trials, both the american college of obstetrics and gynecology (acog) and the society of maternal fetal medicine (smfm) recommend iv ampicillin and iv erythromycin for 2 days, followed by an oral regimen of amoxicillin and erythromycin for 5 days. due to the recent limited availability of erythromycin, azithromycin has been used a substitute. there have been observational studies showing no difference in duration of pregnancy between azithromycin and erythromycin, however no randomized controlled trial has been carried out to our knowledge. this study performs a cluster randomized controlled trial to examine the efficacy of azithromycin versus erythromycin as a component of the "latency antibiotics" used to prolong pregnancy in pprom patients.

Eligibility criteria:
inclusion criteria: * pregnancy at 22 weeks 0 days to 32 weeks 6 days of gestation. * rupture of membranes confirmed by biochemical testing. * membrane rupture within the past 36 hours. * cervical dilation 3 cm or less and 4 or fewer contractions within 60-minutes at the time of admission. * age ≥18 and \<50 years. exclusion criteria: * non-reassuring fetal heart tracing, vaginal bleeding, chorioamnionitis or any indication for delivery at admission. * allergy to penicillin, erythromycin, or azithromycin. * multiple gestations.

Keywords: pprom latency antibiotics prom